← Leaderboards
Juan Marugan
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeHigh Throughput ScreeningScreeningCollaborationsPharmaceutical ChemistryDrug DiscoveryValidationLeadExtramural ActivitiesResearch PersonnelInformaticsUnited States National Institutes Of HealthBiologyDrug DevelopmentTherapeutic DevelopmentSmall Molecule TherapeuticsAssay DevelopmentBaseNew TechnologySynthesis ChemistryNovel TherapeuticsPharmaceutical PreparationsPhenotypeLead Optimization
Grant awards (200)
Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)$418,442
ZIA · FY2025 · TR · contact PI
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Epilepsy and Neurodegenerative diseases$418,442
ZIA · FY2025 · TR · contact PI
Progression of Metarrestin that Reduces PNC Prevalence and Elucidation of its Mechanism of Action$418,442
ZIA · FY2025 · TR · contact PI
Small molecule agonists of the relaxin 1 receptor$418,442
ZIA · FY2025 · TR · contact PI
Discovery of Novel Modulators of the Human D2 Dopamine Receptor$418,442
ZIA · FY2025 · TR · contact PI
CD206 activators as novel immunomodulators$418,442
ZIA · FY2025 · TR · contact PI
Evaluation of cAbl allosteric inhibitors in Gaucher-Parkinson$418,442
ZIA · FY2025 · TR · contact PI
Identification of small molecule that selectively modulate Ghrelin receptor (GHSR1a) b-arrestin signaling as a new therapeutic approach for the treatment of addiction$418,442
ZIA · FY2025 · TR · contact PI
Identification of novel agonist of the Relaxin family peptide receptor 2 (RXFP2) as potential new therapeutics for testicular maldescent$418,442
ZIA · FY2025 · TR · contact PI
PAC1 receptor antagonists as potential treatments for depression and atherosclerosis associated with chronic stress$418,442
ZIA · FY2025 · TR · contact PI
New approaches for facilitating transcytosis of biologically active molecules$278,962
ZIA · FY2025 · TR · contact PI
Antibody-calcineurin inhibitor conjugates that target T-cells to target refractory inflammation$274,995
ZIA · FY2025 · TR · contact PI
Assay for Small-Molecule Antagonists of the TSH Receptor$209,221
ZIA · FY2025 · TR · contact PI
Identifying novel antibiotics by targeting the EF-Tu complex formation$139,481
ZIA · FY2025 · TR · contact PI
Identification of Modulators of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease$139,481
ZIA · FY2025 · TR · contact PI
CD206 activators as novel immunomodulators$491,448
ZIA · FY2024 · TR · contact PI
Identification of novel agonist of the Relaxin family peptide receptor 2 (RXFP2) as potential new therapeutics for testicular maldescent$491,448
ZIA · FY2024 · TR · contact PI
PAC1 receptor antagonists as potential treatments for depression and atherosclerosis associated with chronic stress$491,448
ZIA · FY2024 · TR · contact PI
Identification of small molecule that selectively modulate Ghrelin receptor (GHSR1a) b-arrestin signaling as a new therapeutic approach for the treatment of addiction$491,448
ZIA · FY2024 · TR · contact PI
Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)$491,448
ZIA · FY2024 · TR · contact PI
Progression of Metarrestin that Reduces PNC Prevalence and Elucidation of its Mechanism of Action$491,448
ZIA · FY2024 · TR · contact PI
Small molecule agonists of the relaxin 1 receptor$491,448
ZIA · FY2024 · TR · contact PI
Characterizing inhibitors of tyrosine protein kinase ABL1 (ABL1) in human glioblastoma$491,448
ZIA · FY2024 · TR · contact PI
Discovery of Novel Modulators of the Human D2 Dopamine Receptor$491,448
ZIA · FY2024 · TR · contact PI
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Epilepsy and Neurodegenerative diseases$491,431
ZIA · FY2024 · TR · contact PI
Selective targeting of immune-specific glucocorticoid-sensitive genes$327,632
ZIA · FY2024 · TR · contact PI
Identification of modulators of TRAP1$245,724
ZIA · FY2024 · TR · contact PI
Assay for Small-Molecule Antagonists of the TSH Receptor$245,724
ZIA · FY2024 · TR · contact PI
Identifying novel antibiotics by targeting the EF-Tu complex formation$163,816
ZIA · FY2024 · TR · contact PI
Modulators of RPS14 with broad antiviral activity$163,816
ZIA · FY2024 · TR · contact PI
Identification of GIRK2 channel modulators$163,816
ZIA · FY2024 · TR · contact PI
Identification of Modulators of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease$163,816
ZIA · FY2024 · TR · contact PI
Development of high-throughput CETSA target engagement assays$163,816
ZIA · FY2024 · TR · contact PI
Identification of novel agonist of the Relaxin family peptide receptor 2 (RXFP2) as potential new therapeutics for testicular maldescent$310,142
ZIA · FY2023 · TR · contact PI
Identification of small molecule that selectively modulate Ghrelin receptor (GHSR1a) b-arrestin signaling as a new therapeutic approach for the treatment of addiction$310,142
ZIA · FY2023 · TR · contact PI
Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)$310,142
ZIA · FY2023 · TR · contact PI
Assay for Small-Molecule Antagonists of the TSH Receptor$310,142
ZIA · FY2023 · TR · contact PI
Discovery of Novel Modulators of the Human D2 Dopamine Receptor$310,142
ZIA · FY2023 · TR · contact PI
Small molecule agonists of the relaxin 1 receptor$310,142
ZIA · FY2023 · TR · contact PI
Progression of Metarrestin that Reduces PNC Prevalence and Elucidation of its Mechanism of Action$310,142
ZIA · FY2023 · TR · contact PI
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Alzheimer's Disease$310,142
ZIA · FY2023 · TR · contact PI
Identification of Modulators of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease$310,142
ZIA · FY2023 · TR · contact PI
PAC1 receptor antagonists as potential treatments for depression and atherosclerosis associated with chronic stress$310,142
ZIA · FY2023 · TR · contact PI
Characterizing inhibitors of tyrosine protein kinase ABL1 (ABL1) in human glioblastoma$310,142
ZIA · FY2023 · TR · contact PI
Target validation of CD206 activators$240,788
ZIA · FY2023 · TR · contact PI
Modulators of RPS14 with broad antiviral activity$240,788
ZIA · FY2023 · TR · contact PI
Identification of GIRK2 channel modulators$240,788
ZIA · FY2023 · TR · contact PI
Development of high-throughput CETSA target engagement assays$240,788
ZIA · FY2023 · TR · contact PI
Identification of modulators of TRAP1$125,849
ZIA · FY2023 · TR · contact PI
Identification of small molecule RXFP3 ligands$125,849
ZIA · FY2023 · TR · contact PI
Selective targeting of immune-specific glucocorticoid-sensitive genes$125,849
ZIA · FY2023 · TR · contact PI
Identifying novel antibiotics by targeting the EF-Tu complex formation$125,849
ZIA · FY2023 · TR · contact PI
Identification of small molecule that selectively modulate Ghrelin receptor (GHSR1a) b-arrestin signaling as a new therapeutic approach for the treatment of addiction$425,400
ZIA · FY2022 · TR · contact PI
Discovery of Novel Modulators of the Human D2 Dopamine Receptor$425,400
ZIA · FY2022 · TR · contact PI
Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)$425,400
ZIA · FY2022 · TR · contact PI
High Throughput Screening for Biased Agonists of the TSH Receptor that Activate the Beta-arrestin pathway$425,400
ZIA · FY2022 · TR · contact PI
Progression of Metarrestin that Reduces PNC Prevalence and Elucidation of its Mechanism of Action$425,400
ZIA · FY2022 · TR · contact PI
Identification of Modulators of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease$425,400
ZIA · FY2022 · TR · contact PI
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel$425,400
ZIA · FY2022 · TR · contact PI
PAC1 receptor antagonists as potential treatments for depression and atherosclerosis associated with chronic stress$425,400
ZIA · FY2022 · TR · contact PI
Identification of novel agonist of the Relaxin family peptide receptor 2 (RXFP2) as potential new therapeutics for testicular maldescent$425,400
ZIA · FY2022 · TR · contact PI
Characterizing inhibitors of tyrosine protein kinase ABL1 (ABL1) in human glioblastoma$425,400
ZIA · FY2022 · TR · contact PI
Assay for Small-Molecule Antagonists of the TSH Receptor$425,400
ZIA · FY2022 · TR · contact PI
Developing inhibitors for PIP4Kgamma for Huntington's disease$425,400
ZIA · FY2022 · TR · contact PI
Small molecule agonists of the relaxin 1 receptor$425,400
ZIA · FY2022 · TR · contact PI
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Alzheimer's Disease$425,400
ZIA · FY2022 · TR · contact PI
Target validation of CD206 activators$259,560
ZIA · FY2022 · TR · contact PI
Development of high-throughput CETSA target engagement assays$259,560
ZIA · FY2022 · TR · contact PI
Modulators of RPS14 with broad antiviral activity$259,560
ZIA · FY2022 · TR · contact PI
Selective targeting of immune-specific glucocorticoid-sensitive genes$146,225
ZIA · FY2022 · TR · contact PI
Identification of small molecule RXFP3 ligands$146,225
ZIA · FY2022 · TR · contact PI
Identification of modulators of TRAP1$146,225
ZIA · FY2022 · TR · contact PI
Identifying novel antibiotics by targeting the EF-Tu complex formation$146,225
ZIA · FY2022 · TR · contact PI
Small molecule agonists of the relaxin 1 receptor$350,724
ZIA · FY2021 · TR · contact PI
Characterizing inhibitors of tyrosine protein kinase ABL1 (ABL1) in human glioblastoma$350,724
ZIA · FY2021 · TR · contact PI
Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)$350,724
ZIA · FY2021 · TR · contact PI
High Throughput Screening for Biased Agonists of the TSH Receptor that Activate the Beta-arrestin pathway$350,724
ZIA · FY2021 · TR · contact PI
Assay for Small-Molecule Antagonists of the TSH Receptor$350,724
ZIA · FY2021 · TR · contact PI
Discovery of Novel Modulators of the Human D2 Dopamine Receptor$350,724
ZIA · FY2021 · TR · contact PI
Progression of Metarrestin that Reduces PNC Prevalence and Elucidation of its Mechanism of Action$350,724
ZIA · FY2021 · TR · contact PI
Developing inhibitors for PIP4Kgamma for Huntington's disease$350,724
ZIA · FY2021 · TR · contact PI
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Alzheimer's Disease$350,724
ZIA · FY2021 · TR · contact PI
Identification of Modulators of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease$350,724
ZIA · FY2021 · TR · contact PI
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel$350,724
ZIA · FY2021 · TR · contact PI
PAC1 receptor antagonists as potential treatments for depression and atherosclerosis associated with chronic stress$350,724
ZIA · FY2021 · TR · contact PI
Identification of novel agonist of the Relaxin family peptide receptor 2 (RXFP2) as potential new therapeutics for testicular maldescent$350,724
ZIA · FY2021 · TR · contact PI
Identification of small molecule that selectively modulate Ghrelin receptor (GHSR1a) b-arrestin signaling as a new therapeutic approach for the treatment of addiction$350,724
ZIA · FY2021 · TR · contact PI
Target validation of CD206 activators$201,957
ZIA · FY2021 · TR · contact PI
Functionally Selective Ligands for the D2 Dopamine Receptor$201,957
ZIA · FY2021 · TR · contact PI
Development of high-throughput CETSA target engagement assays$201,957
ZIA · FY2021 · TR · contact PI
Cryopreservants for organ transplantation$201,957
ZIA · FY2021 · TR · contact PI
Assay for Small-Molecule Antagonists of the TSH Receptor$305,662
ZIA · FY2020 · TR · contact PI
Discovery of Novel Modulators of the Human D2 Dopamine Receptor$305,662
ZIA · FY2020 · TR · contact PI
Small molecule agonists of the relaxin 1 receptor$305,662
ZIA · FY2020 · TR · contact PI
Progression of Metarrestin that Reduces PNC Prevalence and Elucidation of its Mechanism of Action$305,662
ZIA · FY2020 · TR · contact PI
Developing inhibitors for PIP4Kgamma for Huntington's disease$305,662
ZIA · FY2020 · TR · contact PI
PAC1 receptor antagonists as potential treatments for depression and atherosclerosis associated with chronic stress$305,662
ZIA · FY2020 · TR · contact PI
Identification of Modulators of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease$305,662
ZIA · FY2020 · TR · contact PI
Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)$305,662
ZIA · FY2020 · TR · contact PI
High Throughput Screening for Biased Agonists of the TSH Receptor that Activate the Beta-arrestin pathway$305,662
ZIA · FY2020 · TR · contact PI
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel$305,662
ZIA · FY2020 · TR · contact PI
Characterizing inhibitors of tyrosine protein kinase ABL1 (ABL1) in human glioblastoma$305,662
ZIA · FY2020 · TR · contact PI
Identification of small molecule that selectively modulate Ghrelin receptor (GHSR1a) b-arrestin signaling as a new therapeutic approach for the treatment of addiction$305,662
ZIA · FY2020 · TR · contact PI
Identification of novel agonist of the Relaxin family peptide receptor 2 (RXFP2) as potential new therapeutics for testicular maldescent$305,662
ZIA · FY2020 · TR · contact PI
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Alzheimer's Disease$305,662
ZIA · FY2020 · TR · contact PI
Functionally Selective Ligands for the D2 Dopamine Receptor$186,552
ZIA · FY2020 · TR · contact PI
Cryopreservants for organ transplantation$112,360
ZIA · FY2020 · TR · contact PI
Characterization of human progenitor Tay-Sachs neurons$112,360
ZIA · FY2020 · TR · contact PI
Targeting Six1/Eya2 for fibrosis$112,360
ZIA · FY2020 · TR · contact PI
Development of high-throughput CETSA target engagement assays$112,360
ZIA · FY2020 · TR · contact PI
Target validation of CD206 activators$112,360
ZIA · FY2020 · TR · contact PI
Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)$250,290
ZIA · FY2019 · TR · contact PI
Identification of small molecule that selectively modulate Ghrelin receptor (GHSR1a) b-arrestin signaling as a new therapeutic approach for the treatment of addiction$250,290
ZIA · FY2019 · TR · contact PI
Identification of novel agonist of the Relaxin family peptide receptor 2 (RXFP2) as potential new therapeutics for testicular maldescent$250,290
ZIA · FY2019 · TR · contact PI
PAC1 receptor antagonists as potential treatments for depression and atherosclerosis associated with chronic stress$250,290
ZIA · FY2019 · TR · contact PI
Development of a novel pharmacologic strategy to activate normal pathways of differentiation in melanoma$250,290
ZIA · FY2019 · TR · contact PI
Identification of Modulators of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease$250,290
ZIA · FY2019 · TR · contact PI
Developing inhibitors for PIP4Kgamma for Huntington's disease$250,290
ZIA · FY2019 · TR · contact PI
Progression of Metarrestin that Reduces PNC Prevalence and Elucidation of its Mechanism of Action$250,290
ZIA · FY2019 · TR · contact PI
Discovery of Novel Modulators of the Human D2 Dopamine Receptor$250,290
ZIA · FY2019 · TR · contact PI
High-throughput screening to identify IP6K1 inhibitors as novel therapeutics for psychiatric disorders$250,290
ZIA · FY2019 · TR · contact PI
Characterizing inhibitors of tyrosine protein kinase ABL1 (ABL1) in human glioblastoma$250,290
ZIA · FY2019 · TR · contact PI
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel$250,290
ZIA · FY2019 · TR · contact PI
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Alzheimer's Disease$250,290
ZIA · FY2019 · TR · contact PI
Small molecule agonists of the relaxin 1 receptor$250,290
ZIA · FY2019 · TR · contact PI
Assay for Small-Molecule Antagonists of the TSH Receptor$250,290
ZIA · FY2019 · TR · contact PI
Identification of inhibitors of the Six1/Eya interaction using high throughput screening$250,290
ZIA · FY2019 · TR · contact PI
High Throughput Screening for Biased Agonists of the TSH Receptor that Activate the Beta-arrestin pathway$250,290
ZIA · FY2019 · TR · contact PI
SMN Ubiquitin Ligase$250,290
ZIA · FY2019 · TR · contact PI
A drug based approach for integrin-mediated alleviation for muscular dystrophy$250,290
ZIA · FY2019 · TR · contact PI
Mutant Gs G-protein corrector$250,290
ZIA · FY2019 · TR · contact PI
Identification of GPR32 agonists as potential anti-inflammatory agents$132,650
ZIA · FY2019 · TR · contact PI
Functionally Selective Ligands for the D2 Dopamine Receptor$132,650
ZIA · FY2019 · TR · contact PI
Identification of GPR120 Beta-arrestin-2 Biased Agonists for the Treatment of Insulin resistance$132,650
ZIA · FY2019 · TR · contact PI
Identification of small molecules that increase activity of the huntingtin antisense promoter for the potential treatment of Huntington Disease$132,650
ZIA · FY2019 · TR · contact PI
Identification of small molecules that decrease the activity of the huntingtin gene promoter for the potential treatment of Huntington Disease$132,650
ZIA · FY2019 · TR · contact PI
Identification of modulators of TRAP1$40,790
ZIA · FY2019 · TR · contact PI
HTS of Rab9 promoter activators$40,790
ZIA · FY2019 · TR · contact PI
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel$245,080
ZIA · FY2018 · TR · contact PI
SMN Ubiquitin Ligase$245,080
ZIA · FY2018 · TR · contact PI
High Throughput Screening for Biased Agonists of the TSH Receptor that Activate the Beta-arrestin pathway$245,080
ZIA · FY2018 · TR · contact PI
Identification of inhibitors of the Six1/Eya interaction using high throughput screening$245,080
ZIA · FY2018 · TR · contact PI
Assay for Small-Molecule Antagonists of the TSH Receptor$245,080
ZIA · FY2018 · TR · contact PI
Discovery of Novel Modulators of the Human D2 Dopamine Receptor$245,080
ZIA · FY2018 · TR · contact PI
Small molecule agonists of the relaxin 1 receptor$245,080
ZIA · FY2018 · TR · contact PI
Progression of Metarrestin that Reduces PNC Prevalence and Elucidation of its Mechanism of Action$245,080
ZIA · FY2018 · TR · contact PI
Developing inhibitors for PIP4Kgamma for Huntington's disease$245,080
ZIA · FY2018 · TR · contact PI
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Alzheimer's Disease$245,080
ZIA · FY2018 · TR · contact PI
Identification of Modulators of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease$245,080
ZIA · FY2018 · TR · contact PI
Mutant Gs G-protein corrector$245,080
ZIA · FY2018 · TR · contact PI
Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)$245,080
ZIA · FY2018 · TR · contact PI
Identification of novel agonist of the Relaxin family peptide receptor 2 (RXFP2) as potential new therapeutics for testicular maldescent$245,080
ZIA · FY2018 · TR · contact PI
A drug based approach for integrin-mediated alleviation for muscular dystrophy$245,080
ZIA · FY2018 · TR · contact PI
M2-selective Macrophage Toxicity$127,680
ZIA · FY2018 · TR · contact PI
Functionally Selective Ligands for the D2 Dopamine Receptor$127,680
ZIA · FY2018 · TR · contact PI
Identification of GPR120 Beta-arrestin-2 Biased Agonists for the Treatment of Insulin resistance$127,680
ZIA · FY2018 · TR · contact PI
HTS of Rab9 promoter activators$37,462
ZIA · FY2018 · TR · contact PI
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel$251,630
ZIA · FY2017 · TR · contact PI
Mutant Gs G-protein corrector$251,630
ZIA · FY2017 · TR · contact PI
HttpolQ-GFP cytotoxicity$251,630
ZIA · FY2017 · TR · contact PI
Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)$251,630
ZIA · FY2017 · TR · contact PI
Identification of Inhibitors of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease$251,630
ZIA · FY2017 · TR · contact PI
Identification of GPR120 Beta-arrestin-2 Biased Agonists for the Treatment of Insulin resistance$251,630
ZIA · FY2017 · TR · contact PI
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Alzheimer's Disease$251,630
ZIA · FY2017 · TR · contact PI
HTS of Rab9 promoter activators$251,630
ZIA · FY2017 · TR · contact PI
SMN Ubiquitin Ligase$251,630
ZIA · FY2017 · TR · contact PI
High Throughput Screening for Biased Agonists of the TSH Receptor that Activate the Beta-arrestin pathway$251,630
ZIA · FY2017 · TR · contact PI
Identify inhibitors of the Six1/Eya interaction using high throughput screening$251,630
ZIA · FY2017 · TR · contact PI
Assay for Small-Molecule Antagonists of the TSH Receptor$251,630
ZIA · FY2017 · TR · contact PI
Discovery of Novel Modulators of the Human D2 Dopamine Receptor$251,630
ZIA · FY2017 · TR · contact PI
Small molecule agonists of the relaxin 1 receptor$251,630
ZIA · FY2017 · TR · contact PI
HTS Assay for Identification of Compounds that Reduce PNC Prevalence$251,630
ZIA · FY2017 · TR · contact PI
M2-selective Macrophage Toxicity$44,666
ZIA · FY2017 · TR · contact PI
Identification of Novel Antivirals against Venezuelan Equine Encephalitis Virus (VEEV)$44,666
ZIA · FY2017 · TR · contact PI
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Alzheimer's Disease$226,982
ZIA · FY2016 · TR · contact PI
A drug based approach for integrin-mediated alleviation for muscular dystrophy$226,982
ZIA · FY2016 · TR · contact PI
HTS of Rab9 promoter activators$226,982
ZIA · FY2016 · TR · contact PI
SMN Ubiquitin Ligase$226,982
ZIA · FY2016 · TR · contact PI
High Throughput Screening for Biased Agonists of the TSH Receptor that Activate the Beta-arrestin pathway$226,982
ZIA · FY2016 · TR · contact PI
Identify inhibitors of the Six1/Eya interaction using high throughput screening$226,982
ZIA · FY2016 · TR · contact PI
High Throughput Screening (HTS) for Akt/mTORC2: Identification of Novel Inhibitors$226,982
ZIA · FY2016 · TR · contact PI
Identification of Small Molecule that act on gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome$226,982
ZIA · FY2016 · TR · contact PI
Identification Of Small Molecules that Specifically Induce DNA Re-replication in Cancer Cells$226,982
ZIA · FY2016 · TR · contact PI
Assay for Small-Molecule Antagonists of the TSH Receptor$226,982
ZIA · FY2016 · TR · contact PI
Discovery of Novel Modulators of the Human D2 Dopamine Receptor$226,982
ZIA · FY2016 · TR · contact PI
Small molecule agonists of the relaxin 1 receptor$226,982
ZIA · FY2016 · TR · contact PI
HTS Assay for Identification of Compounds that Reduce PNC Prevalence$226,982
ZIA · FY2016 · TR · contact PI
HttpolQ-GFP cytotoxicity$226,982
ZIA · FY2016 · TR · contact PI
High throughput screening for SMA$226,982
ZIA · FY2016 · TR · contact PI
Small molecule antagonists of the relaxin 1 receptor$226,982
ZIA · FY2016 · TR · contact PI
Identification of GPR120 Beta-arrestin-2 Biased Agonists for the Treatment of Insulin resistance$226,982
ZIA · FY2016 · TR · contact PI
qHTS to Identify Inhibitors of the Lipid Kinase PI5P4K gamma$226,982
ZIA · FY2016 · TR · contact PI
Identification of Inhibitors of the N370S Mutant Form of Glucocerebrosidase as a Potential Therapy for Gaucher Disease$226,982
ZIA · FY2016 · TR · contact PI
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel$226,982
ZIA · FY2016 · TR · contact PI
Synaptamide analogs (GPR110)$226,960
ZIA · FY2016 · TR · contact PI
M2-selective Macrophage Toxicity$37,474
ZIA · FY2016 · TR · contact PI
Identification of Novel Antivirals against Venezuelan Equine Encephalitis Virus (VEEV)$37,474
ZIA · FY2016 · TR · contact PI
HTS of Rab9 promoter activators$114,000
ZIA · FY2015 · TR · contact PI
Small molecule inhibitor of MBNL1-poly(CUG) RNA binding$114,000
ZIA · FY2015 · TR · contact PI
High Throughput Screen for Inhibitors of Influenza NS1 Protein Function$114,000
ZIA · FY2015 · TR · contact PI